Comparative Pharmacology
Head-to-head clinical analysis: CYCLOSET versus PARLODEL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CYCLOSET versus PARLODEL.
CYCLOSET vs PARLODEL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cycloset (bromocriptine mesylate) is a dopamine D2 receptor agonist. It improves glycemic control in type 2 diabetes by resetting hypothalamic circadian rhythms, thereby reducing hepatic glucose production and increasing insulin sensitivity. It also suppresses the release of very low-density lipoprotein from the liver.
Dopamine D2 receptor agonist; inhibits prolactin secretion by binding to pituitary and hypothalamic D2 receptors.
1.6 mg to 2.4 mg administered orally once daily at bedtime. Titrate by 0.8 mg every 2 weeks based on glycemic response and tolerability.
Parkinson disease: initial 1.25 mg orally twice daily, increase by 2.5 mg/day every 2-4 weeks; usual range 15-30 mg/day. Hyperprolactinemia: initial 1.25-2.5 mg orally once daily, titrate to 2.5 mg twice daily; maintenance 2.5-15 mg/day.
None Documented
None Documented
Terminal elimination half-life is 4–6 hours in patients with normal renal function; clinically, steady-state is reached within 24 hours.
Terminal elimination half-life: 12-14 hours (biphasic, initial half-life 6-8 hours); clinical context: steady-state achieved in 2-3 days.
Renal: ~90% (30% unchanged, rest as inactive metabolites); fecal: ~10%.
Renal: approximately 60% as metabolites, 6% as unchanged drug; biliary/fecal: approximately 40% as metabolites and unchanged drug.
Category C
Category C
Dopamine Agonist / Antidiabetic
Dopamine Agonist